Glycogen phosphorylase (GP) is the key enzyme for glycogen degradation. GP inhibitors (GPi-s) are glucose lowering agents that cause the accumulation of glucose in the liver as glycogen. Glycogen metabolism has implications in beta cell function. Glycogen degradation can maintain cellular glucose levels, which feeds into catabolism to maintain insulin secretion, and elevated glycogen degradation levels contribute to glucotoxicity. The purpose of this study was to assess whether influencing glycogen metabolism in beta cells by GPi-s affects the function of these cells.
Introduction
Cellular glycogen content depends on the net synthesis and degradation of glycogen. Glycogen synthase is responsible for glycogen synthesis, while glycogen phosphorylase (GP) catalyses the breakdown of glycogen to glucose. The two enzymes are regulated in an opposing fashion; only one of them is active at any one time (Stalmans et al., 1990) . GP is a heterodimeric enzyme that possesses seven allosteric binding sites (Agius, 2015; Hayes et al., 2014) . The allosteric binding sites are potential targets for allosteric modulation by pharmacological agents. GP inhibitors (GPi-s), with a few exceptions, are not selective for the liver, muscle and brain isoforms of GP (Agius, 2007) . Hence, the current GPi-s are likely to block all GP activity in cells regardless of the proportions of GP isoforms. GP activation induces the production of hepatic glucose and modulates blood glucose levels. Consequently, GPi-s were investigated as possible anti-diabetic agents to reduce blood glucose levels by inducing the storing of glucose in the form of glycogen. GPi-s have been tested in human clinical studies and have reached phase II trials (Henke, 2012) .
In the endocrine pancreas the beta cells are responsible for the synthesis and secretion of insulin, a hormone that promotes glucose uptake in tissues like skeletal muscle or white adipose tissue. Insulin secretion is induced by glucose uptake, followed by glucose breakdown through glycolysis and mitochondrial oxidation leading to increases in ATP levels. This increased production of ATP leads to the closing of ATP-sensitive potassium channels (K ATP ) and to increased calcium influx. Calcium influx induces the fusion of insulin-rich granules with the cell membrane leading to insulin secretion (MacDonald et al., 2005) . Since glucose is the major regulator of beta cell function, persistent hyperglycaemia combined with peripheral insulin resistance in type 2 diabetic conditions results in the beta cells being overworked to maintain normal blood glucose levels (Abdul-Ghani, 2013; Cerf, 2013; Halban et al., 2014; MacDonald et al., 2005) . Hence, chronic exposure to high glucose leads to the exhaustion of beta cells, progressive beta cell failure and, eventually, to the loss of beta cells (Cerf, 2013) .
Nevertheless, there are pathways that can counteract beta cell failure and loss. One such pathway is paracrine/autocrine insulin signalling through the insulin receptor (InsR). InsR signalling is a complex process that is initiated by the binding of insulin to its receptor and leads to the autophosphorylation of the InsR (Boucher et al., 2014) . InsR autophosphorylation sets in motion a set of downstream phosphorylation events that involve the activation of PI3K as well as the mechanistic target of rapamycin complex 1 and 2 (mTORC1 and 2). These master regulators induce the phosphorylation of Akt and ribosomal protein S6 kinase B1 (p70S6K) and contribute to the stabilization and activation of pancreatic and duodenal homeobox 1 (PDX1) that is essential for beta cell survival and growth (Humphrey et al., 2010; Johnson et al., 2006; Kaneto et al., 2015) . These effects culminate in improved beta cell mass, survival, growth and function [e.g. improved glucose-stimulated insulin secretion (GSIS)] (Boucher et al., 2014; Elghazi et al., 2009; Fujimoto et al., 2009; Rhodes et al., 2013) .
Glycogen is abundant in pancreatic beta cells as compared with α, δ and pancreatic polypeptide-secreting cells, which only contain glycogen in negligible quantities (Graf et al., 1984; Malaisse et al., 2001) . The abundance of glycogen in beta cells suggests a unique role for glycogen in these cells. However, the effect of intracellular glycogen content on beta cell function is still debatable (Graf et al., 1981; Malaisse, 2016; Mir-Coll et al., 2016 ). In the current study, we set out to investigate the effects of increased glycogen levels on beta cells.
Methods

Statement on the experimental approach
All animal and cell experiments were performed and analysed by blinded researchers.
In all experiments, animals were randomly allocated to the different experimental groups. In the cell experiments, the position of the treatments on the plates was randomly changed from experiment to experiment.
Animal studies
Male C57/Bl6J mice (Charles River Laboratories, Wilmington, MA, USA) were used as C57/Bl6J mice are good models for obesity-induced diabetes. Animal experiments were approved by the Institutional Animal Care and Use Committee at the University of Debrecen and the National Board for Animal Experimentation (7/2010 DE MÁB) and were carried out according to the NIH guidelines 'Guide for the care and use of laboratory animals', and applicable national laws. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015) .
We used C57/Bl6 male mice (6 months of age, 20-25 g). The experiments took place at the Animal Facility of the University of Debrecen under specific pathogen free (SPF) conditions. Mice were fed either normal chow (10 kcal% of fat) (SAFE, Augy, France) or a high-fat diet (HFD, hypercaloric diet, 60% fat content, Research Diets, Inc., New Brunswick, NJ, USA) for 3 months. These mice were either left untreated or treated with 90 mg·kg À1 bodyweight of KB228 (in PBS containing 1% DMSO) as a single i.p. injection once a week for at least 3 weeks before they were killed. Mice were killed by cervical dislocation at the end of treatment. Tissues were collected and processed as specified. Mice were randomly assigned to either the vehicle or KB228 group. In the chowfed groups, there were eight vehicle-treated and eight KB228-treated mice, while in the HFD-fed groups, there were 10 vehicle-treated and 10 KB228-treated mice.
No more than six mice were housed in each cage (standard block shape 365 × 207 × 140 mm, surface 530 cm 2 ; 1284 L Eurostandard Type II. L from Techniplast)
with Lignocel Select Fine (J. Rettenmaier und Söhne, Germany) as bedding. Mice had paper tubes to enrich their environment. Dark/light cycle was 12 h, and temperature 22 ± 1°C. Cages were changed once a week, on the same day. Mice had ad libitum access to food and water (sterilized tap water). The animal facility was overseen by a veterinarian. A total of 36 mice was used in this study, group sizes are shown in the figure captions.
Glucose-induced insulin release test
The glucose-induced insulin release test was performed as described previously (Bai et al., 2011) . Briefly, mice were fasted overnight, and the next morning,~50 μL blood was collected (baseline fasting insulin). After the mice had received 2 g·kg
À1
glucose by oral gavage, the blood was collected into heparintreated tubes every 15 min for up to 60 min. Plasma was prepared from these samples and plasma insulin content was measured using a commercial Mouse Insulin ELISA Kit (Mercodia, Uppsala, Sweden) following the manufacturer's instructions.
Histochemical assessment of glycogen content in the pancreas
The glycogen content of pancreatic tissue was determined by periodic acid Schiff (PAS) staining. Sections, 5 μm, of the pancreatic tissue were prepared and subjected to deparaffinization, followed by hydration with water and oxidation in 0.5% periodic acid solution for 20 min. After being rinsing in distilled water, the sections were placed in Schiff reagent for 15 min; then washed in lukewarm tap water for 5 min, and counterstained in haematoxylin for 2-3 min. After extensive washing with tap water, these sections were dehydrated and covered. Microscopic images were acquired with a Zeiss Axioscope 20 microscope using Plan NEOFLUOR 40× objective at 25°C. Images were processed using Leica Application Suite V4.8 software. Glycogen content was determined by measuring the intensity with Image J software, where more intensive PAS staining correlates with higher glycogen content.
Insulin immunohistochemistry and islet size determination
Slides of pancreatic tissue were deparaffinized, endogenous peroxidase activity was blocked [3% hydrogen peroxide in methanol on 5 μm paraffin sections for 15 min at room temperature (RT)] and then the slides were rinsed briefly with PBS. Non-specific binding was blocked by incubating the slides for 1 h in 1% BSA diluted in PBS. To detect insulin, guinea pig polyclonal insulin antibody (DAKO, Glostrup, Denmark; 1:100) was applied overnight at 4°C in 1% BSA diluted in PBS. After extensive washing with PBS, the slides were stained with Envision one-step polymer HRP (BioGenex Fremont CA, USA) (90 min). The colour was developed for 2 min using nickel 3,3 0 -diaminobenzidine tetrachloride as a substrate for antibody-coupled HRP (1.6 mM DAB, 140 mM NaCl, 90 mM NiSO 4 , 100 mM Na-acetate, 3 mM H 2 O 2 , pH 6.6). After the sections had been rinsed in 50 mM Tris-HCl (pH 7.4), the colour was enhanced by incubating the sections for 2 min in 2% cobalt chloride (in 50 mM Tris-HCl, pH 7.2). Sections were then rinsed in distilled water and counterstained with 1% methyl green solution. A negative immunohistochemical control was included in each run. Microscopic images were acquired with a Zeiss Axioscope 20 microscope using Plan NEOFLUOR 40× objective at 25°C. Images were processed using Leica Application Suite V4.8 software. Islet size was determined in μm 2 by using Image J software.
Cell culture
MIN6 cells, a generous gift from Dr J. Miyazaki (Osaka University Medical School, Japan) (Miyazaki et al., 1990) , were cultured in DMEM, 15% fetal calf serum, 1% Lglutamine, 1% penicillin-streptomycin, 50 μM 2-mercaptoethanol and 25 mM glucose. Treatments were performed in 5.5 mM glucose.
Biochemical glycogen determination
MIN6 cells were seeded at a concentration of 10 × 10 5 cells . 10 cm À3 petri dish in 5.5 mM DMEM medium. One day after treatment, cells were removed by scraping and collected into Eppendorf tubes. The potassium hydroxide (KOH)-ethanol glycogen extraction method was used for extraction of glycogen and degradation to glucose. After the second ethanol wash, the supernatant was evaporated in a SpeedVac and glycogen pellets were resuspended in distilled water, then the phenol-sulfuric acid assay was applied. Three times the volume of concentrated H 2 SO 4 was added to each sample followed by 10 min of shaking at 500 rpm at RT. After adding 5% phenol solution to the samples, we determined the cellular glycogen content spectrophotometrically. Absorbance was determined at 450 nm.
Electron microscopy (EM)
After 1 day of GPi or vehicle treatment, pellets of the cell samples were processed for electron microscopic investigation according to the ferrocyanide-reduced osmium method described in Karnovsky et al. (1971) and Robinson et al. (1982) . Briefly, cells were fixed in 3% glutaraldehyde dissolved in 0.1 M cacodylate buffer (pH: 7.4) containing 5% sucrose for 1 h at RT. After being washed several times in cacodylate buffer (pH: 7.4), the cells were post-fixed in ferrocyanide-reduced osmium (2% osmium tetroxide and 3% potassium ferrocyanide dissolved in 0.1 M cacodylate buffer, pH: 7.4) for 2 h at RT. Following several washes in cacodylate buffer (pH: 7.4), the cells were dehydrated and embedded into Durcupan ACM resin. Ultrathin sections were cut, collected on Formvar-coated single-slot grids and counterstained with uranyl acetate and lead citrate. These sections were examined with a JEOL 1010 transmission electron microscope and photographed at a magnification of 6000-10 000× with an Olympus Veleta CCD camera. Digitalized images were processed with Adobe Photoshop CS5 software. Morphometric assessment was accomplished as follows. The EM pictures of at least 10 different cells from each group were analysed. The individual glycogen particles were counted, and then their area and circumference (both in μm) were determined by using Image J software. Values are expressed as a ratio between the total/individual circumference of the glycogen particles and the crosssectional area of the cell. As a control for the specificity of the staining, a group of cells underwent the same EM staining protocol but without the addition of potassium ferrocyanide to osmium tetroxide ( Figure 2E ).
Confocal microscopy
MIN6 cells were grown on glass coverslips for 1 day, then starved in glucose-free medium (XF Assay Medium Modified DMEM containing 0 mM glucose, 1% P/S, 1% L-glutamine, 10% FBS, Seahorse Bioscience) overnight. The cells were then charged with 500 μM of the fluorescent D-glucose analogue 2NBDG (Cayman Chemicals Company, Ann Arbour, MI, USA] in uptake buffer (pH 7.4, 138 mM NaCl, 5.5 mM D-glucose, 5 mM KCl, 1 mM MgCl 2 , 1.5 mM CaCl 2 , 10 mM HEPES) for 3 h followed by incubation in 5.5 mM glucosecontaining medium for 1 day. Cells were then fixed with 100% methanol for 20 min at À20°C, then rinsed three times with 1× PBS. The cells were permeabilized with 1% Triton X-100 in PBS for 5 min, blocked with 1% BSA in PBS for 1 h and then incubated with primary monoclonal rabbit antibody for InsRβ (Cell signalling; 1:50) in a moist chamber overnight at 4°C followed by incubation with the secondary antibody (Alexa Fluor ® 647 donkey anti-rabbit IgG (H + L), Life Technologies, 1:1000) diluted in blocking solution for 1 h at RT. Coverslips were rinsed three times with 1× PBS, and then cells were stained with DAPI (NucBlue® Fixed cell Stain ReadyProbes ™ reagent, Life Technologies, Carlesbad, CA, USA) and rinsed in PBS again. Confocal images were acquired with a Leica TCS SP8 confocal microscope using HC PL APO CS2 63x/1.40 oil immersion objective on a DMI6000 CS microscope at 25°C. The following lasers were used: OPSL 488 for 2NDBG, Diode 638 for Alexa Fluor 647 and 405 visible for DAPI. Images were processed using LAS X 2.0.1.14392 software. Non-specific binding of the secondary antibodies was checked in control experiments.
PDX1 promoter assay
Luciferase reporter assays were performed as described previously (Bai et al., 2011) . Cells were seeded at a concentration of 1.5 × 10 5 MIN6 cells per well in six-well plates and were treated with GPi-s for 1 day. At the same time, cells were transfected with β-galactosidase reporter gen with Cytomegalovirus promoter plasmid (1 μg) and -6500STF-1luc plasmid (Sharma et al., 1996) (5 μg). Luciferase activity was measured using standard procedures; luciferase activity was expressed as luciferase activity/β-galactosidase activity, and the values were transformed to fold change compared with the control. The -6500STF-1luc plasmid was a generous gift from Dr M. Montminy (Salk Institute, La Jolla, CA, USA). The promoter insert ( + 68 to À 6500 BP) is of rat origin. To assess its applicability for murine models, we performed a sequence alignment of the promoter sequences and found 82% identity between the promoter sequence of rat and murine Pdx1. Upon densitometry, control samples were considered to be 1 and values are expressed as fold change relative to the controls to reduce unwanted variations.
Gene expression and RT-qPCR
Reverse transcription coupled with RT-qPCR reactions were performed similarly as in Nagy et al. (2013) . Briefly, total RNA was prepared using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. A total of 2 μg of RNA was used for reverse transcription (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems, Foster City, CA, USA). The resulting cDNA, diluted 10X, was used for qPCR reactions (PCRBIOSYSTEMS, qPCRBIO SyGreen Mix Lo-ROX, UK). The qPCR reactions were performed using the Light-Cycler system (Roche Applied Science, Mannheim, Germany). Primers are listed in Table 1 . Expression was normalized to the geometric mean of three control genes (cyclophillin, 18S, 36B4 or Gapdh). Control samples were considered to be 1 and values are expressed as fold change relative to the controls to reduce unwanted variation.
Protein extraction and Western blotting
Cells were incubated on ice in lysis buffer then homogenized using a 26 G needle in the lysis buffer (250 mM saccharose, 20 mM HEPES, 1 mM EDTA, 1 mM EGTA, 0.5% Nonidet P-40). Lysates were cleared by centrifugation. Supernatants contained the cytoplasmic fraction and the pellet contained Table 1 Primers used in RT-qPCR reactions
Name
Forward Reverse
the nuclear fraction. Pellets were further extracted first using buffer A (350 mM saccharose, 10 mM pH 7.9 HEPES, 3.3 mM MgCl 2 , 10 mM KCl) then buffer B (the same as A excepting with 250 mM saccharose). The samples were then sonicated and cleared by centrifugation. PDX1 was measured in the cytoplasmic and nuclear fractions; all other elements were measured in the cytoplasmic fractions. Western blotting experiments were performed as described previously (Bai et al., 2011) . Blots were probed with the antibodies listed in Table 2 . Upon densitometry, control samples were considered to be 1 and values are expressed as fold change relative to controls to reduce unwanted variations. Signals were developed using enhanced chemiluminescence and were captured by the Fluorchem FC2 gel documentation system (Alpha Innotech, San Leandro, CA, USA).
Insulin release in MIN6 cells
MIN6 cells were plated then pre-incubated in DMEM for 1 and 2 days with or without inhibitors. Before the measurements, the medium was changed in each well to 1 mL of 5.5 mM glucose-containing DMEM medium (without adding more glucose). After 2 min, a 10 μL sample was taken and diluted further in the medium. Spontaneous and early insulin production by MIN6 cells was measured using a Mouse Insulin ELISA Kit (Mercodia, Winston Salem, NC, USA) following the manufacturer's instructions. After the assay, 1 M NaOH was added to adhered MIN6 cells in six-well plates, and the total protein content was determined using BCA reagent (Pierce ™ BCA Protein Assay Kit, Thermofisher, Walthman, MA, USA). Insulin secretion was normalized to protein content.
Glucose-induced insulin release in MIN6 cells
GSIS from MIN6 cells was determined using a static incubation protocol as in Johnson (2007 
Determination of total insulin protein in MIN6 cells
The same number of MIN6 cells was seeded in 24-well plate in 5.5 mM DMEM medium. After 1 day of treatment, cells were scraped and collected. Cells were extracted using 1.5% HCl in 70% ethanol overnight. After the extraction, insulin content in each sample was measured using a Mouse Insulin ELISA Kit (Mercodia, Winston Salem, NC, USA) following the manufacturer's instructions. Insulin content was normalized Table 2 List of antibodies used in the study 
Determination of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR)
Oxygen consumption and ECAR were determined using an XF96 Flux Analyser (Seahorse Biosciences, North Billerica, MA, USA). MIN6 cells were seeded in 96-well assay plates and treated with GPi-s for 1 and 2 days, followed by oximetry. After the baseline had been recorded, OCR and ECAR were recorded every 3 min up to 60 min to follow the effects of GPi-s. Antimycin (10 μM) was used for distinguishing mitochondrial from non-mitochondrial oxygen consumption (proton leak). The final reading took place at 1 h. OCR and ECAR were measured with respect to the cell number (10 5 cells), and readings were analysed and plotted. concentration were recorded as changes in the ratio of the emission/excitation (340/380 nm). After a stable baseline had been reached (60 s), cells were stimulated with 20 mM glucose.
Determination of K i
Kinetic measurements were performed as in Osz et al. (1999) .
In silico screening for glycogen-binding proteins
The database containing a list of proteins with potential association with glycogen was assembled from multiple against the effective inhibitor concentrations were replotted to give the secondary plots, which were analysed and showed the K i for the inhibitor.
BJP
L Nagy et al.
queries using the UniProt database (http://www.uniprot.org). The resulting list was manually revised, and redundancies in the list were removed manually.
Statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All data are presented as average ± SEM, and n denotes the number of experiments. Statistical significance was determined using one-way ANNOVA with Tukey honest significant difference (HSD).
In the animal study to assess statistical significance Student's unpaired, two-tailed t-test was used. Post hoc tests were conducted only if the data in the experimental groups showed F distribution and ther was no significant variance in homogeneity. Technical replicates in a run were averaged and yielded a value for a biological replicate. The n number in the figure legends denotes the number of biological replicates used for statistical analysis. * Indicates statistically significant differences between vehicle and treated groups at P < 0.05.
Chemicals
Unless stated otherwise, all chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) including CP-316819. The other GPi-s, namely KB228 and BEVA335, were synthesized in the laboratory of Dr L. Somsák (Figure 1 A-C). The inhibitors were used in concentrations close to their K i to ensure pharmacological specificity: KB228 at 3 μM (K i = 937 nM) (Nagy et al., 2013) , BEVA335 at 1.5 μM (K i = 411 nM) (Bokor et al., 2013; Bokor et al., 2015) and CP-316819 at 0.5 μM (K i = 220 nM). The K i of CP-316819 was determined using the same methodology (Osz et al., 1999) as that used for KB228 and BEVA335 in order to gain comparable K i values ( Figure 1D ).
Figure 2
The effects of the GPi-s on glycogen content and on the size of glycogen particles in beta cells. 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b,c) .
Results
GP inhibition increases glycogen content and the size of glycogen particles in beta cells
In our study, we have used the glucose analogue GPi-s KB228 ( Figure 1A ) (Nagy et al., 2013) and BEVA335 ( Figure 1B ) (Bokor et al., 2013 (Bokor et al., , 2015 that have mixed-type inhibitory effects on GP (Agius, 2007; Somsák et al., 2008b) . In addition, we used CP-316819 ( Figure 1C ) as a reference GPi (Torres et al., 2011; Rath et al., 2000) this is an indole-2-carboxamide compound that binds to the novel allosteric site. To gain insights into the role of glycogen metabolism in beta cells, we used MIN6 cells, a well-established model for beta cells (Miyazaki et al., 1990) . Firstly, we assessed the presence of glycogen in MIN6 cells by incorporating a fluorescently labelled derivative of D-glucose (2NBDG) into glycogen followed by confocal microscopy. 2NBDG fluorescence appeared in MIN6 cells and displayed a punctate pattern of various sizes in the cytosol (Figure 2A) . Furthermore, when MIN6 cells were treated with GPi-s, the cellular glycogen content was enhanced, as shown by the biochemical determination of glycogen ( Figure 2B ), indicating active glycogen metabolism in MIN6 cells. This observation was verified on EM sections of GPi-treated MIN6 cells stained for glycogen ( Figure 2C) . Furthermore, image analysis enabled the measurement of the circumference of glycogen particles that we used as a proxy for glycogen particles on the surface. The circumference of glycogen particles also increased upon GPi treatment ( Figure 2D,E) . Taken together, the findings indicate that GPi-s increase the cellular glycogen content in cells and the circumference of the glycogen particles suggesting a bigger surface area is covered by glycogen particles.
Figure 3
GPi-s induce InsR signalling in MIN6 cells. MIN6 cells were treated with GPi-s for 1 day at the indicated concentrations. In these cells, (A) phosphorylation of InsRβ subunit on tyrosine 1345, Akt on Serine 473 and S6K on threonine 389 were assessed by Western blot analysis of phosphorylated and non-phosphorylated forms of the respective proteins. One representative blot is presented. (B) Pdx1 promoter activity was determined by luciferase assay (n = 5, in duplicate) and mRNA levels (n = 5, in duplicate or triplicate) by RT-qPCR. PDX1 protein levels were determined in the cytoplasmic and nuclear fractions of MIN6 cell lysates by Western blotting. One representative blot is presented here. (C) In GPi-treated cells, insulin mRNA expression (n = 5, in duplicate or triplicate), the corresponding protein levels (n = 5) and (D) insulin release (n = 6) were determined. (E) GSIS were analysed by an insulin ELISA Kit (n = 5). Transcription and translation TCF7L2 Transcription factor 7-like 2 (HMG box transcription factor 4) (T-cell-specific transcription factor 4) (T-cell factor 4) (TCF-4) (hTCF-4) NR1D1 Nuclear receptor subfamily 1 group D member 1 (Rev-erbα) (V-erbA-related protein 1) (EAR-1)
EIF2B5
Translation initiation factor eIF-2B subunit ε (eIF-2B GDP-GTP exchange factor subunit ε) TCF7L2 TCF7L2 protein (transcription factor 7-like 2 (T-cell specific, HMG-box), isoform CRA_e) GP inhibition improves beta cell survival and beta cell function
In GPi-treated MIN6 cells, the phosphorylation of InsRβ on tyrosine 1345 was elevated ( Figure 3A) . Effectors lying downstream of InsRβ, such as mTORC1 and mTORC2, were also activated, as indicated by the enhanced phosphorylation of p70S6 K protein on threonine 389 and of Akt on serine 473, respectively ( Figure 3A) . Furthermore, we observed enhanced Pdx1 promoter activity and mRNA expression upon GPi treatment that subsequently led to a large increase in PDX1 protein content both in the cytoplasmic and nuclear fraction ( Figure 3B ). Insulin expression and protein levels were also increased upon GPi treatment ( Figure 3C ). We also observed a tendency for an increase in non-stimulated insulin release, whereas the increases in GSIS were more pronounced upon GPi treatment ( Figure 3D , E). To explain these surprising data, we hypothesized that increases in glycogen content and glycogen particle size may provide additional surface area for binding and interaction with proteins involved in the regulation of beta cell function. We performed an in silico screen and identified more than 100 potential glycogen bound proteins (Table 3) . Figure 4A ), similar to other reports of non-stimulated MIN6 cells (Shang et al., 2009; Zhang et al., 2001) . We continued our investigations by performing co-localization studies using confocal microscopy. We opted for co-localization studies in intact cells by immunofluorescence due to the tenacious nature of glycogen. In biochemical assays where classical procedures have been followed, in which cells are lysed, glycogen is isolated and the glycogen-bound proteins are analysed, it is likely that non-specific proteins will bind to glycogen during the preparation. Due to the lack of commercially available anti-glycogen antibody, we opted for charging glycogen with 2NBDG. However, the charging of cells with 2NBDG was not 100% efficient; we observed less fluorescently labelled glycogen particles than on EM pictures, making the evaluation of the fraction of glycogen-bound InsRs impossible. The other suspected partner, InsRβ, was stained with a specific antibody. When the two images were superimposed, a fraction of the InsRβ and glycogen particles co-localized ( Figure 4B ). This observation was in accord with the GPi-induced phosphorylation of InsRβ downstream targets. Taken together, these findings indicate that GPi-s can induce InsR signalling, probably through glycogen particles that interact with InsRβ.
To verify the involvement of the insulin signalling pathway, we inhibited PI3K, a key participant in the InsR cascade, with wortmannin (1 μM, 1 h). Treatment of MIN6
Figure 4
Co-localization of glycogen particles and the β subunit of InsR in MIN6 cells. (A) Localization of InsRβ (IRβ) and (B) its co-localization with glycogen in MIN6 cells were assessed in confocal microscopy experiments (n = 8). Glycogen was charged with a fluorescent glucose analogue (2NBDG, green), and InsRβ was immunostained using an InsRβ-specific antibody and Alexa Fluor 647 secondary antibody (red). Nuclei of the cells were stained using DAPI (blue). Bars represent 5 μm, and on the inlay of panel A, the bar represents 3.5 μm. InsRβ staining was completely lost when the primary antibody was omitted during immunostaining. On the inlay of panel A, brightness and contrast were adjusted. cells with wortmannin efficiently blocked the GPi-induced increases in mRNA and protein levels of PDX1 ( Figure 5A ) and insulin ( Figure 5B ), as well as basal insulin release ( Figure 5C ). However, GPi-induced GSIS was only slightly reduced by wortmannin ( Figure 5D ).
KB228 and CP316819 improve GSIS of beta cell
We next investigated the effects of GP inhibition on the 'classical' pathway of insulin release. Firstly, we observed that BEVA335 did not influence most features of the 'classical' insulin secretion pathway; therefore, we omitted BEVA335 from further investigations and used only KB228 and CP-316819. Interestingly, the effects of KB228 and CP-316819 on the 'classical' insulin release pathway lasted longer (2 days) than their effects on InsR signalling (all experiments described in the previous sections were performed after 1 day of treatment).
CP-316819 enhanced glycolysis (as measured by ECAR) ( Figure 6A ) and mitochondrial oxidation (as measured by OCR) ( Figure 6B ). Furthermore, we observed similar tendencies with KB228. Enhanced mitochondrial oxidation was translated into increases in glucose-stimulated calcium influx ( Figure 6C ). These effects were discernible both at 1 and 2 days of treatment; however, calcium uptake and the subsequent insulin release were more pronounced 2 days after treatment ( Figure 6E ).
Repeated GPi treatment improves GSIS in vivo
We investigated the effects of repeated administration of KB228 in mice fed either a regular, chow diet or HFD. PAS staining showed elevated pancreatic glycogen content upon KB228 treatment under both feeding regimens ( Figure 7A ). In GPi-treated HFD-fed mice, we found a significant increase in the size of the islets of Langerhans compared with vehicle-treated animals; Langerhans islet size also tended to be larger in chow-fed mice treated with KB228 ( Figure 7B ). Repeated administration of KB228 had a tendency to improve glucose-induced insulin release ( Figure 7C ).
Discussion
In this study, we showed that the pharmacological inhibition of GP and the consequent increase in cellular glycogen content were associated with the induction of the insulin signalling pathway, beta cell proliferation and glucoseinduced insulin release. The role of glycogen in beta cells is controversial. Earlier studies (Malaisse et al., 1993; Malaisse et al., 1977) suggest that glycogenolysis provides glucose for glycolysis and mitochondrial oxidation in beta cells under starvation conditions and, hence, facilitates insulin release. Under extremely high glucose concentrations, as in diabetes, glycogen accumulation in beta cells may lead to glucotoxicity (Malaisse, 2016; Malaisse et al., 1992) . However, a recent study by Mir-Coll provided contradictory results by showing Figure 5 Inhibition of PI3K by wortmannin (WM) abolished the effects of GPi-s in MIN6 cells. MIN6 cells were treated with GPi-s as before, and a subset of MIN6 cells was treated with wortmannin (1 μM, for the last hour of the GPi treatment). In these cells, mRNA (n = 5, in duplicate) and protein levels (n = 5, in duplicate) of (A) PDX1 and (B) insulin were determined. For determination of insulin, total protein was extracted and insulin was quantified by a Mouse Insulin ELISA Kit. Finally, (C) non-stimulated, spontaneous (n = 5) and (D) glucose-induced (n = 5) insulin secretion were assessed.
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that glycogen metabolism is not required for the maintenance of beta cell function. Furthermore, Mir-Coll (Mir-Coll et al., 2016) showed that glycogen accumulation alone is not sufficient to trigger dysfunction, apoptosis and progression to diabetes in beta cells.
Our findings support those studies that show a physiological role for glycogen in beta cells (Doherty et al., 2001; Graf et al., 1981; Graf et al., 1984; Hellman et al., 1969; Malaisse, 2016; Malaisse et al., 1993) . We cannot provide a well-established explanation for the apparent discrepancy between these observations. Nevertheless, GPiinduced increases in glycogen are probably lower in our study than in others (Malaisse et al., 1992) and may involve a different pathway. Similarly, differences in glycogen accumulation may account for the lack of glucotoxicity in our models (Malaisse et al., 1992) .
Figure 6
The GPi-s KB228 and CP-316819 induce the 'classical' insulin secretion pathway in MIN6 cells. MIN6 cells were treated with GPi-s for 1 and 2 days. In these cells, (A) ECAR and (B) cellular OCR (n = 7, in quadruplicate or octuplicate) were determined by a Seahorse extracellular flux analyser. (C) Calcium influx was induced by 20 mM glucose and was determined by Fura-2 AM staining (n = 5, 6-8 area of interest). Furthermore, GSIS (D) (n = 5) was determined by a Mouse Insulin ELISA Kit. Insulin baseline was measured at 1 mM glucose concentration, while glucose stimulation was performed with 20 mM glucose similarly to the measurement of Ca 2+ -oscillation.
Figure 7
In vivo effects of KB228 treatment. Chow-and HFD-fed C57/Bl6J male mice underwent repeated vehicle or KB228 treatment (weekly, 90 mg·kg À1 i.p) for at least three consecutive weeks. After they had been killed, (A) glycogen content was evaluated on PAS-stained slides. Representative images are presented (scale bar = 50 μm). PAS positivity was evaluated by measuring the intensity of staining with Image J software. (B) The size of the islets of Langerhans was determined on insulin-immunostained histological sections (scale bars = 50 μm). Representative images are shown. Islet size was determined in μm 2 by using Image J software. We used Student's t-test (unpaired, two-tailed) for statistical analysis. (C) Glucoseinduced increases in serum insulin were determined using an insulin-specific ELISA kit.
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Previous studies have considered glycogen as a glucose reserve, while we suggest an additional structural role, according to which glycogen particles with elevated surface area contribute to the induction of InsR signalling. Either glycogen itself induces InsRβ autophosphorylation or, more likely, glycogen serves as a scaffold for the members of the InsR signalling pathway, as suggested by the in silico screening for glycogen-binding proteins. Other large cellular polymers [e.g. poly (ADP-ribose) (Tartier et al., 2003; Bai, 2015) ] or fuzzy proteins (Fuxreiter, 2012; Sharma et al., 2015) were shown to act as interactive surfaces for large protein complexes in a similar fashion as we suggest here for glycogen.
GPi-induced biochemical changes involve several downstream targets of InsR including PI3K, mTORC1, mTORC2, Akt and PDX1. The involvement of PI3K was demonstrated by the use of wortmannin, which abolished GPi-induced increases in PDX1 and insulin expression, and non-stimulated insulin secretion. However, wortmannin only modestly reduced GPi-mediated increases in GSIS, suggesting that other, as yet unknown, pathway(s) may also be involved in this effect of GPi. The known biological functions of the other downstream factors affected by GPi fit well into the GPi-induced phenotype. The activation of PDX1 has been associated with improved transcription and translation of insulin in beta cells (Kaneto et al., 2015) . Activation of mTORC1 and mTORC2 are prerequisites for cell growth and division (Sarbassov et al., 2005) , similar to PDX1 (Fujimoto et al., 2009) , while Akt is a survival signal in beta cells (Elghazi et al., 2009) .
Another route stimulated by GPi-s was the classical or triggering pathway of insulin secretion. Here, we showed that KB228 and CP-316819 induced glycolysis, mitochondrial oxidation and glucose-induced calcium transients -hallmarks of the classical pathway. In line with these observations, we also showed a tendency towards improved GSIS in mice. Yet we cannot explain how GPi-s stimulate the classical pathway. Nevertheless, GPi-s were reported to induce mitochondrial oxidation in previous reports (Baker et al., 2005; Nagy et al., 2013 ). An easy explanation would be that InsR signalling can induce mitochondrial oxidation (Cheng et al., 2010; Liu et al., 2009) and this is what stands at the root of the phenotype. However, the activation of the insulin secretion cascade lasted for longer (up to 2 days of treatment) than the induction of InsR signalling (up to 1 day of treatment), suggesting additional mechanism(s).
GPi-s were originally designed to be used as glycogenlowering agents that trap excess glucose in the form of glycogen, mainly in the liver (Henke, 2012; Agius, 2007; Somsák et al., 2008a) . Several GPi-s were tested in clinical trials and passing phase I, confirming the safety of these drugs (Henke, 2012) . Namely, CP-316819 (Pfizer, a drug used in our current study), AVE56588 (Sanofi-Aventis) and GSK1362885 (GlaxoSmithKline) completed phase I, while CP-368296 (Ingliforib, Pfizer) and PSN-357 (Prosidion, now Astellas Pharma) advanced to phase II (for review, see Henke, 2012) . Although, the proproliferative effects of GPi-s on beta cells raise safety concerns, as if these are general these GPi-s could affect a wide variety of cells. Nevertheless, Favaro et al. (2012) and Lee et al. (2004) showed that GPi-s are antiproliferative on pancreatic adenocarcinoma cells suggesting a cell or tissue-specific proliferative effect. Clinical studies on GPi-s were halted after phase II, but the reasons were not communicated (Henke et al., 2012) . Our study suggests that another cell type, beta cells, can be also targeted by GPi-s, and GPi-s exert beneficial effects on beta cells. Our data have revealed the positive effects of mild increases in glycogen on beta cells and demonstrate that GPi-s have the potential to act as beta cell preserving agents. These data raise the possibility of repurposing GPi-s from the original indication as agents to inhibit hepatic glucose output in type II diabetes to a new indication that is the preservation of beta cells in the context of type I or type II diabetes.
Conclusions
We showed that structurally different GPi-s can induce the synthesis and secretion of insulin and provoke survival signals in a cellular model of beta cells. We propose that these effects of GPi-s are exerted through modulating InsR signalling, where glycogen serves as a matrix for clustering members of the signalling complex. In mice, the repeated administration of KB228, a GPi, led to the enlargement of the islets of Langerhans and tended to increase glucoseinduced insulin secretion. Taken together, these findings have revealed a new target tissue for GPi-s and suggest that these drugs should be repurposed to preserve beta cell function.
